- Comp & Benefits
- Work/Life Balance
- Senior Management
- Culture & Values
- Career Opportunities
I worked at Allos Therapeutics full-time (more than 3 years)Doesn't RecommendNegative OutlookDisapproves of CEODoesn't RecommendNegative OutlookDisapproves of CEO
Paid well for good people
Some latitude to do your job
Hugely unrealistic corporate goals
High school clique atmosphere
Sr Mgmt was so greedy and had such an inflated sense of worth that they burned through capital and squandered opportunities
Quick to fire only certain people.
Bought by Spectrum which is amazingly worse.
Advice to Management
You WERE responsible to the staff and company you milked.
BOD - unspeakable disservice in keeping Paul so far past his prime.
Let us know if we're missing any workplace or industry recognition –
Drug developer Allos Therapeutics is looking for the next big breakthrough in the fight against cancer. The company's first FDA-approved drug, Folotyn (pralatrexate), was launched commercially in the US in 2010 to treat a relatively rare blood cancer called peripheral T-cell lymphoma (PTCL). Allos Therapeutics is also investigating the compound as a potential treatment in other oncology applications, including additional forms of lymphoma; Folotyn is also in clinical trial and research studies for non-small cell lung cancer (NSCLC) and bladder and breast cancers.